MD Anderson VC arm joins $25M funding round for cancer drug company

Cancer Focus Fund, a venture capital arm of Houston-based University of Texas MD Anderson Cancer Center, has joined a $25 million series A funding round for Nectin Therapeutics, which develops novel immunotherapies.